The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd.'s prospectus identifies 3,245,595 common shares issuable upon exercise of warrants. The company announced a 50-to-one consolidation of its common shares, effective October 12, 2026. Each 50 issued and outstanding common shares will be exchanged for one new common share, and the ticker symbol will remain MDCX.
No fractional shares will be issued; holders otherwise entitled to a fraction will be rounded down and paid cash in lieu. The company also stated that exercise prices and share counts for outstanding equity awards, convertible securities and warrants will be adjusted proportionately. The company said the consolidation is intended to increase the bid price and enable it to regain compliance with Nasdaq's minimum bid price requirement.
Medicus Pharma Ltd. will effect a 50-to-1 consolidation of its common shares effective October 12, 2026. Trading on a consolidated basis is expected to begin at the commencement of trading on October 12, 2026.
Every 50 issued and outstanding common shares will be exchanged for one new common share. No fractional shares will be issued; holdings that would otherwise produce a fraction will be rounded down to the next whole share, with cash paid in lieu. Voting power and share rights will remain unchanged. Proportionate adjustments will be made to exercise prices and shares issuable upon exercise or conversion of outstanding equity awards, convertible securities and warrants, and to shares under equity incentive plans. The company name and MDCX ticker will remain unchanged.
Medicus Pharma Ltd. (MDCX) discloses that its Chief Executive Officer and Executive Chairman, Dr. Raza Bokhari, together with RBx Capital, LP, has beneficial ownership of 4,859,349 common shares of Medicus Pharma, representing 5.3% of the company’s common shares on a beneficial ownership basis.
Dr. Bokhari’s position includes 2,941,176 common shares held directly, 1,125,000 common shares underlying stock options that are currently exercisable or will become exercisable within 60 days, and 793,173 common shares held by RBx Capital, LP, a Delaware limited partnership he controls. RBx Capital’s holdings alone represent 0.9% of the class, based on 89,762,721 common shares outstanding as of September 10, 2026. The securities are held for investment and in connection with Dr. Bokhari’s roles at Medicus Pharma, and the reporting persons may increase or decrease their holdings over time depending on corporate, market, and regulatory considerations.
Medicus Pharma Ltd. (MDCX) filed a prospectus supplement covering 3,245,595 common shares issuable upon exercise of outstanding public warrants at $4.64 per share, expiring November 15, 2029. The supplement incorporates two recent current reports into the existing Form S-1 prospectus.
On September 4, 2026, officers and employees elected to take approximately $1.45 million of cash bonuses in equity, and the company issued an aggregate 8,529,412 restricted common shares based on a Nasdaq closing price of $0.1705 per share. Separately, on September 11, 2026, Medicus Pharma and YA II PN, LTD. mutually terminated a Standby Equity Purchase Agreement that had permitted up to $15.0 million of common share sales, with no borrowings outstanding and no termination fees due.
Medicus Pharma Ltd. (MDCX) reports that on September 11, 2026 it and YA II PN, Ltd. mutually agreed to terminate their Standby Equity Purchase Agreement (SEPA), which had allowed the company to issue and sell up to $15.0 million of common shares. At termination, there were no outstanding borrowings, advance notices, or common shares to be issued under the SEPA, and no fees are due by either party in connection with the termination. Yorkville Securities, LLC, an affiliate of YA II PN, Ltd., remains a sales agent under Medicus Pharma’s Equity Distribution Agreement dated December 29, 2025, as amended.
Medicus Pharma Ltd. (MDCX) reported that on September 4, 2026 it granted an aggregate of 8,529,412 restricted common shares to certain officers and employees who elected to forgo cash bonuses. These shares represent the value of approximately $1.45 million of cash bonuses, converted at $0.1705 per share, the Nasdaq Capital Market closing price on September 3, 2026.
No additional cash consideration changed hands in this issuance, which was made as a private offering exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Medicus Pharma Ltd. (MDCX) reported that Chief Operating Officer Smith Andrew Alasdair received equity awards on September 4, 2026. He was granted stock options for 125,000 common shares at an exercise price of $0.1705 per share, scheduled to vest quarterly in four equal installments over one year and expiring on September 4, 2031. He also acquired 735,294 common shares at $0.1705 per share, bringing his direct common share holdings to 735,458 shares and his option holdings to 125,000 shares; no Rule 10b5-1 trading plan is reported.
Medicus Pharma Ltd. (MDCX) reported that Chief Medical Officer Mehmud Faisal received an equity award on September 4, 2026. He was granted a stock option to acquire 250,000 Common Shares at an exercise price of $0.1705 per share, expiring September 4, 2031, vesting quarterly in four equal installments over one year. He also received a direct grant of 1,470,588 Common Shares at $0.1705 per share, bringing his direct common share holdings to 1,470,588 shares. No Rule 10b5-1 trading plan is reported for these awards.
Medicus Pharma Ltd. (MDCX) reported that Chief Scientific Officer Brennan Edward J. received equity awards on September 4, 2026. He was granted 100,000 stock options with an exercise price of $0.1705 per common share, expiring on September 4, 2031, and 588,235 common shares at $0.1705 per share. The option is scheduled to vest quarterly in four equal installments over one year, and his directly held common share position increased to 674,735 shares. No Rule 10b5-1 trading plan is reported for these awards.
Medicus Pharma Ltd. (MDCX) reported that its President and CFO, Carolyn F. Bonner, received equity-based compensation on September 4, 2026. She was granted options to acquire 250,000 common shares at an exercise price of $0.1705 per share, vesting quarterly in four equal installments over one year and expiring on September 4, 2031. On the same date, she also acquired 1,470,588 common shares at $0.1705 per share, resulting in direct ownership of 1,489,493 common shares. No Rule 10b5-1 trading plan is reported for these awards.